Enrollment Complete in Phase 3 Study of Brepocitinib in DM
Enrollment in Phase 3 VALOR study evaluating brepocitinib in dermatomyositis is now complete, according to Priovant Therapeutics. Data are anticipated in the second half of calendar year 2025, with a potential New Drug Application (NDA) submission to follow. Brepocitinib is a dual selective inhibitor of oral tyrosine kinase 2 (TYK2) inhibitor and Janus kinase (JAK1) […]